Velsera Technology Paves the Way for Advanced Cancer Diagnostics with FDA Approval of Illumina TruSight™ Oncology Comprehensive IVD

Empowered by Velsera’s Knowledge Base and Tumor Profiling Expertise Across U.S. Laboratories

BOSTON, Sept. 16, 2024 /PRNewswire/ — Velsera, a leading global healthcare technology company, is excited to announce that our advanced tumor profiling technology is a key component of the knowledge base that supports the Illumina TruSight™ Oncology (TSO) Comprehensive IVD results report. The knowledge base of TSO Comprehensive integrates Velsera’s cutting-edge tumor profiling technology, enhancing patient care by enabling personalized treatment nationwide.

The collaboration between Velsera and Illumina, initiated in December 2018, was driven by a shared vision to advance cancer diagnostics and enhance the accessibility of targeted therapeutics. Velsera’s Knowledge Base (KB) is integral to the TSO Comprehensive test, empowering laboratories to adopt NGS-based diagnostics with greater ease and precision.

“Our collaboration with Velsera helped deliver the desired vision in the launch of the TruSight™ Oncology Comprehensive test, which is to provide laboratories with an NGS-based, clinically-optimized in vitro diagnostic (IVD) test that simplifies the identification of important cancer biomarkers,” said Nicki Berry, Head of Region-Americas, Illumina. 

Velsera’s KB content is crucial in classifying cancer mutations into evidence of clinical significance or potential clinical significance, thereby enabling more personalized and effective treatment plans for patients.

“Advancing cancer diagnostics and making targeted therapeutics more accessible to healthcare systems, laboratories, and patients worldwide remains our key focus,” said Jamie Littlejohns, CEO of Velsera. “This achievement reflects our technology-enabled commitment to accelerating the translation of research discoveries to improve patient outcomes. By working closely with Illumina, we have contributed to making a cutting-edge diagnostic much more accessible and that will now help many more patients with cancer in the US.”

As the field of precision medicine advances, Velsera is at the forefront, working with industry leaders like Illumina to revolutionize the diagnostics landscape. Together, Velsera and its collaborators are accelerating the path to market for IVD solutions and setting a new standard for the entire sequencing market, delivering faster and more precise biomarker identification that directly enhances patient care.

About Velsera:

Velsera’s mission is to be the discovery, evidence generation, and clinical delivery platform for precision medicine. We help experts in clinical diagnostics and life sciences make better decisions about providing the right therapy to the right patients at the right time. Velsera was founded in 2023 as a result of the merger of Seven Bridges, PierianDx and UgenTec and operates in the US, Europe and Asia. For more information, visit www.velsera.com.

Media Contact:
Brian Lassiter
Manager, Commercial Marketing
Velsera
383209@email4pr.com
(857) 357-3060 | ext 3060

View original content to download multimedia:https://www.prnewswire.com/news-releases/velsera-technology-paves-the-way-for-advanced-cancer-diagnostics-with-fda-approval-of-illumina-trusight-oncology-comprehensive-ivd-302248632.html

SOURCE Velsera